MX2015009803A - Composiciones que comprenden 15-ohepa y metodos para usar las mismas. - Google Patents

Composiciones que comprenden 15-ohepa y metodos para usar las mismas.

Info

Publication number
MX2015009803A
MX2015009803A MX2015009803A MX2015009803A MX2015009803A MX 2015009803 A MX2015009803 A MX 2015009803A MX 2015009803 A MX2015009803 A MX 2015009803A MX 2015009803 A MX2015009803 A MX 2015009803A MX 2015009803 A MX2015009803 A MX 2015009803A
Authority
MX
Mexico
Prior art keywords
ohepa
compositions
methods
same
fatty liver
Prior art date
Application number
MX2015009803A
Other languages
English (en)
Other versions
MX364646B (es
Inventor
John Climax
Jonathan Rowe
Kevin Duffy
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of MX2015009803A publication Critical patent/MX2015009803A/es
Publication of MX364646B publication Critical patent/MX364646B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a las composiciones, formulaciones y métodos para el tratamiento de trastornos de hígado graso, tales como enfermedad de hígado graso no alcohólico (EHGNA) y esteatohepatitis no alcohólica (EHNA) y sus secuelas por la administración de 15-OHEPA.
MX2015009803A 2013-01-30 2014-01-24 Composiciones que comprenden 15-ohepa y métodos para usar las mismas. MX364646B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Publications (2)

Publication Number Publication Date
MX2015009803A true MX2015009803A (es) 2015-10-29
MX364646B MX364646B (es) 2019-05-03

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009803A MX364646B (es) 2013-01-30 2014-01-24 Composiciones que comprenden 15-ohepa y métodos para usar las mismas.
MX2019005082A MX2019005082A (es) 2013-01-30 2015-07-29 Composiciones que comprenden 15-ohepa y metodos para usar las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019005082A MX2019005082A (es) 2013-01-30 2015-07-29 Composiciones que comprenden 15-ohepa y metodos para usar las mismas.

Country Status (28)

Country Link
US (5) US20150224076A1 (es)
EP (2) EP3058943B1 (es)
JP (2) JP6363104B2 (es)
KR (5) KR20240011872A (es)
CN (2) CN111214464A (es)
AU (2) AU2014211628B2 (es)
BR (1) BR112015018270A2 (es)
CA (1) CA2897343C (es)
CY (1) CY1117209T1 (es)
DK (1) DK2762143T3 (es)
ES (2) ES2564025T3 (es)
GB (1) GB201301626D0 (es)
HK (1) HK1200351A1 (es)
HR (1) HRP20160203T1 (es)
HU (1) HUE026901T2 (es)
IL (3) IL239893A (es)
MX (2) MX364646B (es)
NZ (1) NZ709803A (es)
PH (1) PH12015501582B1 (es)
PL (1) PL2762143T3 (es)
PT (1) PT2762143E (es)
RS (1) RS54584B1 (es)
RU (2) RU2018136872A (es)
SG (2) SG10201806854XA (es)
SI (1) SI2762143T1 (es)
SM (1) SMT201600069B (es)
WO (1) WO2014118097A1 (es)
ZA (2) ZA201505018B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
US20170020836A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease
EP3389647B1 (en) * 2015-12-18 2023-04-05 Afimmune Limited Compositions comprising 15-hepe
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
DE69407949T2 (de) 1993-10-01 1998-05-14 Scherer Corp R P Zusammensetzungen zum verteilen von duftstoffen
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
PL364093A1 (en) 2001-05-30 2004-12-13 Laxdale Limited Coenzyme q (ubiquinone) and eicosapentaenoic acid (epa)
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
MX2007000208A (es) 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
EP2607902B1 (en) 2006-08-08 2017-10-04 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof
KR101461252B1 (ko) * 2007-03-30 2014-11-12 코와 가부시키가이샤 지방간 또는 비알코올성 지방성 간염의 예방 및/또는 치료를 위한 의약
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US8853437B2 (en) * 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2014530841A (ja) 2011-10-19 2014-11-20 ディグニティサイエンシスリミテッド Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
PT2800563T (pt) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3389647B1 (en) 2015-12-18 2023-04-05 Afimmune Limited Compositions comprising 15-hepe

Also Published As

Publication number Publication date
CN105120872B (zh) 2020-01-10
CN111214464A (zh) 2020-06-02
BR112015018270A2 (pt) 2017-07-18
EP3058943B1 (en) 2019-09-25
EP3058943A1 (en) 2016-08-24
GB201301626D0 (en) 2013-03-13
CA2897343C (en) 2021-03-16
RU2671208C2 (ru) 2018-10-30
HRP20160203T1 (hr) 2016-03-25
SMT201600069B (it) 2016-04-29
IL239893A (en) 2017-04-30
US20210244697A1 (en) 2021-08-12
KR20150112995A (ko) 2015-10-07
CA2897343A1 (en) 2014-08-07
JP2016511753A (ja) 2016-04-21
ZA201505018B (en) 2017-01-25
PH12015501582A1 (en) 2015-10-05
CN105120872A (zh) 2015-12-02
CY1117209T1 (el) 2017-04-05
JP2018172409A (ja) 2018-11-08
ES2564025T3 (es) 2016-03-17
KR20210088733A (ko) 2021-07-14
IL265876A (en) 2019-06-30
AU2014211628B2 (en) 2018-04-19
DK2762143T3 (en) 2016-03-07
US20220347147A1 (en) 2022-11-03
PH12015501582B1 (en) 2015-10-05
RU2018136872A (ru) 2018-11-27
EP2762143B1 (en) 2015-12-02
AU2014211628A1 (en) 2015-07-30
SG10201806854XA (en) 2018-09-27
JP6363104B2 (ja) 2018-07-25
KR102274963B1 (ko) 2021-07-08
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
US20150224076A1 (en) 2015-08-13
US20200069626A1 (en) 2020-03-05
RU2015136849A (ru) 2017-03-06
KR20220119524A (ko) 2022-08-29
PL2762143T3 (pl) 2016-06-30
IL251639A0 (en) 2017-06-29
AU2018206685A1 (en) 2018-08-02
PT2762143E (pt) 2016-03-28
EP2762143A1 (en) 2014-08-06
SI2762143T1 (sl) 2016-04-29
HUE026901T2 (en) 2016-07-28
US10813903B2 (en) 2020-10-27
KR102434817B1 (ko) 2022-08-19
IL239893A0 (en) 2015-08-31
KR20230047201A (ko) 2023-04-06
HK1200351A1 (zh) 2015-08-07
MX2019005082A (es) 2019-08-12
MX364646B (es) 2019-05-03
KR102514913B1 (ko) 2023-03-27
SG11201505457PA (en) 2015-08-28
NZ709803A (en) 2020-05-29
WO2014118097A1 (en) 2014-08-07
ZA201605125B (en) 2018-06-27
ES2759448T3 (es) 2020-05-11
RS54584B1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2023008693A (es) Polinucleotidos moduladores.
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
IN2013MU01927A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: AFIMMUNE LIMITED

FG Grant or registration